Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study

Abstract

GA40 conferred treatment benefit over 3 years: sustained low ARR and lesion activity and favorable safety.